{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:17:53Z","timestamp":1794694673490,"version":"4.9.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Elevated low-density lipoprotein cholesterol (LDL-C) is a major contributor to hyperlipidemia and cardiovascular risk. This study examined the association of LDL-C with metabolic abnormalities in a health examination population and investigated whether gypenosides (GPs) protect against LDL-induced cardiomyocyte injury through the miR-223\/NLRP3 axis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional analysis was conducted in 19,862 adults undergoing routine health examinations. In parallel, H9C2 cardiomyocytes were exposed to LDL with or without GPs. Cell viability, cell cycle distribution, wound healing, Matrigel-based tube formation, oxidative stress, inflammatory markers, and miR-223\/NLRP3-related signaling molecules were assessed. A miR-223 inhibitor and the NLRP3 inhibitor MCC950 were used to further examine the mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated LDL-C was more common in middle-aged and older men and was associated with higher blood glucose, white blood cell count, body mass index, systolic blood pressure, total cholesterol, and triglycerides, together with lower HDL-C. In H9C2 cells, LDL induced abnormal proliferative activation and cell-cycle disturbance, reduced wound healing and tube-like network formation, increased ROS, NO, and LDH release, activated the NLRP3\/NF-\u03baB\/p38\/IL-6 pathway, and suppressed miR-223 expression. GPs attenuated these changes, restored miR-223 expression, and reduced inflammatory signaling. Inhibition of miR-223 weakened the protective effects of GPs, whereas MCC950 suppressed LDL-induced inflammatory activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Elevated LDL-C was associated with metabolic and inflammatory disturbances, and LDL directly induced cardiomyocyte injury\n                      <jats:italic>in vitro<\/jats:italic>\n                      . More importantly, Gypenosides markedly alleviated LDL-induced cellular injury by restoring miR-223 expression and suppressing NLRP3-mediated inflammatory signaling. The inhibitory effect of MCC950 further supports a central role for NLRP3 in this process. Together, these findings suggest that Gypenosides may have therapeutic potential for hyperlipidemia-related myocardial injury.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1740653","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:42:09Z","timestamp":1775022129000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Protective effects of gypenosides on LDL-induced myocardial injury through the miR-223\/NLRP3 axis in hyperlipidemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Wei","family":"Peng","sequence":"first","affiliation":[{"name":"Health Management Center, Shiyan Renmin Hospital, Hubei University of Medicine","place":["Shiyan, China"]},{"name":"Department of Preventive Medicine, School of Public Health, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine","place":["Shiyan, China"]},{"name":"Department of Drug Quality Inspection, School of Pharmaceutical Sciences, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Health Management Center, Shiyan Renmin Hospital, Hubei University of Medicine","place":["Shiyan, China"]},{"name":"Department of Preventive Medicine, School of Public Health, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Wang","sequence":"additional","affiliation":[{"name":"Health Management Center, Shiyan Renmin Hospital, Hubei University of Medicine","place":["Shiyan, China"]},{"name":"Department of Preventive Medicine, School of Public Health, Hubei University of Medicine","place":["Shiyan, China"]},{"name":"Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine","place":["Shiyan, China"]},{"name":"Department of Drug Quality Inspection, School of Pharmaceutical Sciences, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Health Management Center, Shiyan Renmin Hospital, Hubei University of Medicine","place":["Shiyan, China"]},{"name":"Department of Preventive Medicine, School of Public Health, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Health Management Center, Shiyan Renmin Hospital, Hubei University of Medicine","place":["Shiyan, China"]},{"name":"Department of Preventive Medicine, School of Public Health, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, School of Public Health, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Health Management Center, Shiyan Renmin Hospital, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[{"name":"Health Management Center, Shiyan Renmin Hospital, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linsheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Pancreatic Surgery, Taihe Hospital, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Health Management Center, Shiyan Renmin Hospital, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifeng","family":"Li","sequence":"additional","affiliation":[{"name":"Health Management Center, Shiyan Renmin Hospital, Hubei University of Medicine","place":["Shiyan, China"]},{"name":"Department of Preventive Medicine, School of Public Health, Hubei University of Medicine","place":["Shiyan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-018-0711-4","article-title":"Cardiorespiratory fitness and cardiovascular disease prevention: an update","volume":"20","author":"Al-Mallah","year":"2018","journal-title":"Curr Atheroscler Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/j.jacc.2020.11.021","article-title":"The global burden of cardiovascular diseases and risks: a compass for global action","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/jmwh.13637","article-title":"Hyperlipidemia prevention and management utilizing lifestyle changes","volume":"69","author":"Giles","year":"2024","journal-title":"J Midwifery Womens Health."},{"key":"B4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12944-019-1171-8","article-title":"Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review","volume":"19","author":"Yao","year":"2020","journal-title":"Lipids Health Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/CH-211232","article-title":"MicroRNA-223-3p inhibits oxidized low-density lipoprotein-mediated NLRP3 inflammasome activation via directly targeting NLRP3 and FOXO3","volume":"81","author":"Xu","year":"2022","journal-title":"Clin Hemorheol Microcirc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.5935\/abc.20170143","article-title":"Large accumulation of collagen and increased activation of mast cells in hearts of mice with hyperlipidemia","volume":"109","author":"Cheng","year":"2017","journal-title":"Arq Bras Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4244\/EIJ-D-23-00606","article-title":"Targeting inflammation in atherosclerosis: overview, strategy and directions","volume":"20","author":"Waksman","year":"2024","journal-title":"EuroIntervention."},{"key":"B8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12944-018-0905-3","article-title":"Dysregulation of cardiac lipid parameters in high-fat high-cholesterol diet-induced rat model","volume":"17","author":"Han","year":"2018","journal-title":"Lipids Health Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","article-title":"Global epidemiology of dyslipidaemias","volume":"18","author":"Pirillo","year":"2021","journal-title":"Nat Rev Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijcard.2017.12.069","article-title":"Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163,641 adults","volume":"260","author":"Zhang","year":"2018","journal-title":"Int J Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1542\/pir.2019-0053","article-title":"Hyperlipidemia","volume":"41","author":"Stewart","year":"2020","journal-title":"Pediatr Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1001\/jama.2023.2307","article-title":"Cardiovascular risk factor prevalence, treatment, and control in US adults aged 20 to 44 years, 2009 to March 2020","volume":"329","author":"Aggarwal","year":"2023","journal-title":"JAMA."},{"key":"B13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.fertnstert.2021.06.002","article-title":"Obesity and infertility: are hyperlipidemia and hyperinsulinemia the bad guys?","volume":"116","author":"Zippl","year":"2021","journal-title":"Fertil Steril."},{"key":"B14","doi-asserted-by":"publisher","first-page":"822","DOI":"10.7326\/M20-4648","article-title":"Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2020 updated U","volume":"173","author":"O'Malley","year":"2020","journal-title":"Ann Intern Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.cellsig.2011.11.003","article-title":"Preconditioning the hyperlipidemic myocardium: fact or fantasy?","volume":"24","author":"Balakumar","year":"2012","journal-title":"Cell Signal."},{"key":"B16","doi-asserted-by":"publisher","first-page":"931931","DOI":"10.3389\/fphys.2022.931931","article-title":"Low-density lipoprotein particles in atherosclerosis","volume":"13","author":"Qiao","year":"2022","journal-title":"Front Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1080\/21655979.2022.2034583","article-title":"Down-regulated HDAC1 and up-regulated microRNA-124-5p recover myocardial damage of septic mice","volume":"13","author":"Nong","year":"2022","journal-title":"Bioengineered."},{"key":"B18","doi-asserted-by":"publisher","first-page":"113206","DOI":"10.1016\/j.celrep.2023.113206","article-title":"ApoE enhances mitochondrial metabolism via microRNA-142a\/146a-regulated circuits that suppress hematopoiesis and inflammation in hyperlipidemia","volume":"42","author":"Phu","year":"2023","journal-title":"Cell Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/nm.3200","article-title":"MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion","volume":"19","author":"Soh","year":"2013","journal-title":"Nat Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41419-017-0020-9","article-title":"NF-\u03baB\/miR-223-3p\/ARID1A axis is involved in Helicobacter pylori CagA-induced gastric carcinogenesis and progression","volume":"9","author":"Yang","year":"2018","journal-title":"Cell Death Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"107931","DOI":"10.1016\/j.exer.2020.107931","article-title":"Gypenosides mediate cholesterol efflux and suppress oxidized LDL induced inflammation in retinal pigment epithelium cells","volume":"191","author":"Biswas","year":"2020","journal-title":"Exp Eye Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"176766","DOI":"10.1016\/j.ejphar.2024.176766","article-title":"Neuroprotective effects of gypenosides: a review on preclinical studies in neuropsychiatric disorders","volume":"978","author":"Liang","year":"2024","journal-title":"Eur J Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1111\/jcmm.13743","article-title":"Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation","volume":"22","author":"Zhang","year":"2018","journal-title":"J Cell Mol Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"11337","DOI":"10.1021\/acs.jafc.8b03903","article-title":"Comparison of the effects and inhibitory pathways of the constituents from Gynostemma pentaphyllum against LPS-induced inflammatory response","volume":"66","author":"Shen","year":"2018","journal-title":"J Agric Food Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"176062","DOI":"10.1016\/j.ejphar.2023.176062","article-title":"The protective effects of uric acid against myocardial ischemia via the Nrf2 pathway","volume":"959","author":"Ma","year":"2023","journal-title":"Eur J Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"175254","DOI":"10.1016\/j.ejphar.2022.175254","article-title":"Puerarin ameliorates myocardial remodeling of spontaneously hypertensive rats through inhibiting TRPC6-CaN-NFATc3 pathway","volume":"933","author":"Yan","year":"2022","journal-title":"Eur J Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00392-025-02833-y","article-title":"A practical guide to the management of dyslipidaemia","volume":"115","author":"Siegel","year":"2026","journal-title":"Clin Res Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pop.2023.08.002","article-title":"Novel pharmacotherapies for hyperlipidemia","volume":"51","author":"Reamy","year":"2024","journal-title":"Prim Care."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.amepre.2024.02.014","article-title":"Hyperlipidemia-attributed deaths in the U","volume":"66","author":"Zheutlin","year":"2024","journal-title":"Am J Prev Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e051121189015","DOI":"10.2174\/1573403X16999201210200342","article-title":"Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review","volume":"17","author":"Alloubani","year":"2021","journal-title":"Curr Cardiol Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12889-018-5196-0","article-title":"Lipid profile and dyslipidemia among school-age children in urban Ghana","volume":"18","author":"Lartey","year":"2018","journal-title":"BMC Public Health."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1111\/jgs.14566","article-title":"Oxidized LDL, gamma-glutamyltransferase and adverse outcomes in older adults","volume":"65","author":"Spoto","year":"2017","journal-title":"J Am Geriatr Soc."},{"key":"B33","doi-asserted-by":"publisher","first-page":"155002","DOI":"10.1016\/j.phymed.2023.155002","article-title":"Salvianolic acid B inhibits atherosclerosis and TNF-\u03b1-induced inflammation by regulating NF-\u03baB\/NLRP3 signaling pathway","volume":"119","author":"Zhao","year":"2023","journal-title":"Phytomedicine."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"155649","DOI":"10.1016\/j.phymed.2024.155649","article-title":"The pathological mechanisms and potential therapeutic drugs for myocardial ischemia reperfusion injury","volume":"129","author":"Zhang","year":"2024","journal-title":"Phytomedicine."},{"key":"B36","doi-asserted-by":"publisher","first-page":"76514","DOI":"10.1007\/s11356-022-23043-3","article-title":"Insights into the pivotal role of statins and its nanoformulations in hyperlipidemia","volume":"29","author":"Singh","year":"2022","journal-title":"Environ Sci Pollut Res Int."},{"key":"B37","first-page":"78","article-title":"Hyperlipidemia: drugs for cardiovascular risk reduction in adults","volume":"95","author":"Last","year":"2017","journal-title":"Am Fam Physician."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1279118","DOI":"10.3389\/fpubh.2023.1279118","article-title":"Progress in studying the impact of hyperlipidemia and statins on rotator cuff injury and repair","volume":"11","author":"Qian","year":"2023","journal-title":"Front Public Health."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.2174\/1389450120666190214141626","article-title":"Structure and function of proprotein convertase subtilisin\/kexin type 9 (PCSK9) in hyperlipidemia and atherosclerosis","volume":"20","author":"Lu","year":"2019","journal-title":"Curr Drug Targets."},{"key":"B40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.biopha.2018.05.024","article-title":"Role of PCSK9 in lipid metabolism and atherosclerosis","volume":"104","author":"Lin","year":"2018","journal-title":"Biomed Pharmacother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/s41401-024-01305-9","article-title":"A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis","volume":"45","author":"Wang","year":"2024","journal-title":"Acta Pharmacol Sin."},{"key":"B42","first-page":"S139","article-title":"Epidemiology and management of hyperlipidemia","volume":"23","author":"Karr","year":"2017","journal-title":"Am J Manag Care."},{"key":"B43","doi-asserted-by":"publisher","first-page":"11687","DOI":"10.3390\/ijms222111687","article-title":"Statin-associated myopathy: emphasis on mechanisms and targeted therapy","volume":"22","author":"Vinci","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.5551\/jat.RV17030","article-title":"Diagnosis and management of statin intolerance","volume":"26","author":"Alonso","year":"2019","journal-title":"J Atheroscler Thromb."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3390\/ph16081152","article-title":"Gypenoside-14 reduces depression via downregulation of the nuclear factor kappa B (NF-kB) signaling pathway on the lipopolysaccharide (LPS)-induced depression model","volume":"16","author":"Jiang","year":"2023","journal-title":"Pharmaceuticals."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e17538","DOI":"10.7717\/peerj.17538","article-title":"Gypenosides exert cardioprotective effects by promoting mitophagy and activating PI3K\/Akt\/GSK-3\u03b2\/Mcl-1 signaling","volume":"12","author":"Zheng","year":"2024","journal-title":"PeerJ."}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1740653\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:42:11Z","timestamp":1775022131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1740653\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":46,"alternative-id":["10.3389\/fnut.2026.1740653"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1740653","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1740653"}}